The incidence of Leydig cell adenomas increases in CD rats fed for 2 years with the hepatic peroxisome proliferator, ammonium perfluorooctanoate (C8). Treatment with C8 increased the serum concentration of estradiol in 2-week gavage studies, and feeding studies at various time points up to 2 years, and was also accompanied by increases in liver weight and hepatic /^-oxidation activity. Since peroxisome proliferators induce both hepatic /9-oxidation and specific cytochrome P450 enzymes, C8 may also induce aromatase (cytochrome P450-19A1), the cytochrome P450 monooxygenase which converts androgens to estrogens. This hypothesis was investigated in the present study. Adult male CD rats were dosed daily by gavage for 14 days with 0, 0.2, 2, 20, or 40 mg C8/ kg body wt. An additional group, the pair-fed control, was fed at a rate matched to the daily consumption by the 40 mg C8/kg group. Treatment with C8 produced a dose-dependent decrease in body weight, and increases in absolute and relative liver weights, and in the protein yield of hepatic microsomes. These C8-induced changes were associated with a 2-fold increase in the serum concentration of estradiol and up to a 16-fold increase in total hepatic aromatase activity. A significant linear correlation was established between serum estradiol and total hepatic aromatase activity. The absolute weights and the aromatase activity of the testes were not affected by C8. Hepatic peroxisomal /3-oxidation activity and the microsomal concentration of total cytochrome P450 were also increased by C8. A comparison of estimated EC50 values suggested that these parameters may be less sensitive to induction by C8 than hepatic aromatase activity. Co-incubation of control liver microsomes with C8 in the aromatase assay for 2 hr dose dependently reduced the apparent aromatase activity. This inhibition of aromatase in vitro but increase in vivo was further investigated using cultured rat hepatocytes. Decreases in aromatase activity were found after up to 42 hr of treatment with C8, but the enzyme activity was increased almost 2-fold after 66 hr. The results of this 1 This work was presented in part at the 1994 Society of Toxicology meeting in Dallas, TX.
Ammonium perfluorooctanoate (C8) is a perfluorinated carboxylic acid derivative, whose wide industrial applications include usage as a plasticizer, lubricant, wetting agent, and emulsifier (Guenther and Victor, 1962) . C8 is not metabolized in rats (Kuslikis et al., 1992; Vanden Heuval et al., 1991) , produces hepatomegaly, and induces hepatic peroxisomes and /^-oxidation activity in rats and mice (Ikeda et al, 1985; Kawashima et al, 1989; Pastoor et al, 1987; Uy-Yu et al, 1990) . These liver effects are common to a structurally diverse class of compounds known as peroxisome proliferators, of which most, including C8 (Cook et al., 1994) , induce hepatocellular carcinoma (reviewed in Gibson and Lake, 1993 ). In 2-year feeding studies in Crl:CD BR (CD) rats, C8 increased the incidence of Leydig cell adenomas (Sibinski, 1987) , hepatocellular carcinomas, and pancreatic acinar cell tumors (Cook et al., 1994) . A series of Ames tests conducted in the presence and absence of metabolic activation showed that C8 is not genotoxic (Griffith and Long, 1980) . Consequently, tumor formation produced by C8 is thought to occur through a nongenotoxic mechanism. Therefore, a possible endocrine-related mechanism of Leydig cell tumorigenesis has been suggested (Cook etai, 1992) . Two-week gavage studies in adult male CD rats showed that C8 dose dependently reduces the serum concentration of testosterone and increases the concentration of estradiol in serum (Cook et al., 1992) and testicular interstitial fluid (Biegel et ai, 1995) . By including an additional control group of rats, dosed with vehicle and fed at the same daily rate as rats receiving the top dose of C8, it was found that the change in serum testosterone, but not estradiol, was related to a dose-dependent reduction in body weight (Cook et al., 1992) .
The increase in serum estradiol induced by C8 in vivo appears to correlate with its ability also to cause peroxisome proliferation in the liver, as measured by /3-oxidation assay (Cook et al., 1992) . Peroxisome proliferators are reported to induce both hepatic /9-oxidation activity and cytochrome P450 (Ayrton et al., 1991; Bacher and Gibson, 1988; Sharma et al., 1988) . Aromatase is the P450-monooxygenase (cytochrome P450-19A1) which converts androgens to estrogens (reviewed by Coffey, 1988) . It has also been shown in adult male CD rats that daily dosing by gavage of 25 mg C8/kg body wt for 2 weeks increases the aromatase activity in liver but not epididymal fat pads, skeletal muscle, or testes (Biegel et al., 1995) . The inability to detect an increase in testicular aromatase activity was unexpected since C8 has been shown to increase estradiol production from cultured Leydig cells (Biegel et al., 1995) . This may be due to the small number of animals used and a low aromatase activity in microsomal samples prepared from whole testes rather than from Leydig cells. These results suggested that C8 increases serum estradiol by inducing aromatase activity in the liver and possibly the Leydig cells. The objective of the present study was to establish a dose-response relationship for C8 and hepatic aromatase activity and to further characterize the effect of C8 on liver aromatase activity in vitro. 
MATERIALS AND METHODS

Materials
Animals.
Eleven-week-old adult male Crl:CD BR (CD) rats were purchased from Charles River Breeding Laboratories (Raleigh, NC), caged individually, and quarantined for 1 week. Tap water and Purina Certified Rodent Chow #5002 meal (Ralston Purina, St. Louis, MO) were provided ad libitum. Animal rooms were illuminated by fluorescent light on a 12-hr light cycle and maintained at a temperature of 23 ± 2°C and a relative humidity of 50 ± 10%.
Study design. Once released from quarantine, rats were ranked by their most recently recorded body weight and assigned by computerized randomization to control or experimental groups. This randomization resulted in no statistical difference (p = 0.98) in group mean body weights.
Dose selection was based on a previous 14-day gavage study in rats, where the lowest dose of 1 mg C8/kg produced small but nonstatistically significant biochemical changes, and 50 mg C8/kg was the maximum dose which produced no deaths but markedly depressed body weight gain (Cook el al., 1992) . In the present study, a maximum dose of 40 mg C8/kg was chosen, and a low dose of 0.2 mg C8/kg was chosen to establish a no effect level. There were six groups of 15 rats each, four of which received 0.2, 2, 20, or 40 mg C8/kg body wt. The study included two control groups which received the vehicle, deionized water. The ad libitum control was allowed free access to diet. Pair-fed control rats were fed the mean amount of diet consumed on the previous day by the rats dosed with 40 mg C8/ kg. This control group was included to assess the effect of reduced body weight on the measured parameters because treatment with C8 is known to reduce dietary intake and body weight (Cook et al., 1992) . Individual food consumption was determined daily for all rats. All rats were dosed daily by gavage using a dose volume of 2 ml/kg, for 14 days (Test Days 1 through 14), based on their individual daily body weight.
Collection of samples. Rats were weighed on Test Day 15 and sacrificed by carbon dioxide asphyxiation. Serum was prepared from blood collected from the vena cava and stored below -60°C. The testes and liver were collected, weighed, and stored in ice-cold SET buffer (250 rriM sucrose, 5.4 DIM ethylenediaminetetraacetic acid (EDTA), 50 mM tris(hydroxymethyl) aminomethane, pH 7.4). The chilled liver tissues and decapsulated testes were homogenized in SET buffer (4 ml/g tissue) by Polytron for 15 sec, and the homogenates were centrifuged at 600g for 15 min at 4°C. The pellets were discarded and the supernatants centrifuged at 15,000g for 15 min at 4°C. The resultant pellet contained the peroxisomal fraction, and the supernatant contained the microsomal fraction. Only the liver peroxisomes were resuspended in chilled SET buffer by Polytron and stored below -60°C. The testicular peroxisomes were discarded. The microsomal fractions (supernatants) were centrifuged at 100,000g for 70 min at 4°C. The microsomal pellets were resuspended in chilled SET buffer by Polytron and stored below -60°C.
The protein concentrations of the peroxisomal and microsomal samples were determined using Bio-Rad protein assay reagent and bovine serum albumin (BSA; fraction V) as the standard (Bradford, 1976) .
Radioimmunoassay. The serum concentration of estradiol was measured using radioimmunoassay kits purchased from Diagnostic Products Corp. (Los Angeles, CA). The intra-and interassay coefficients of variation were <10 and <15%, respectively.
Peroxisomal fi-oxidation. /3-Oxidation activity in the hepatic peroxisome samples was determined using [l- l4 C]palmitoyl-CoA as the substrate, a 10-min reaction time, and approximately 5 fig peroxisomal protein per tube (Lazarow, 1981) . The reaction mixture also contained 1 mM potassium cyanide to inhibit mitochondrial /3-oxidation activity.
Microsomal aromatase activity. Aromatase activity was determined in the microsomes using the tritiated water-release method of Lephart and Simpson (1991) with the following modifications. Hepatic microsomes were diluted to a protein concentration of 1.6 mg/ml in assay buffer (50 mM K 2 HPO 4 , 50 mM KH 2 PO 4 , 1 mM EDTA, pH 7.4). Testicular microsomes were used undiluted in the assay. Each tube contained 100 /A microsomes and 850 fi\ reaction mixture (1.25 fi\ of 1.0 mCi/ml [l/3-3 H]androsten-4-ene-3,17-dione, 176.5 /XM unlabeled androsten-4-ene-3,17-dione, prepared in assay buffer). The assay blanks contained 100/il assay buffer instead of the microsomes. The reaction was initiated by the addition of 50/il of an NADPH-regenerating system (25 mM /5-NADP, 200 mM glucose 6-phosphate, 2 units glucose-6-phosphate dehydrogenase, prepared in assay buffer). The assay tubes were incubated at 37°C for 2 hr for liver and 3 hr for testes, and the reactions were terminated by addition of chloroform. Combined with mixing the aqueous phase with a suspension of 2.5% (w/ v) activated charcoal and 0.25% (w/v) dextran (average molecular weight of 83,000) in deionized water, this procedure removed radiolabeled steroids from the aqueous phase. The release of tritiated water was measured by scintillation counter.
A saturating concentration of substrate was used in this assay. Microsomes from rat ovary and liver were used during the development of this assay. The specificity of the aromatase assay was validated in hepatic microsomes using the inhibitors aminoglutethimide (IC50 = 167 fiM) and 5a-dihydrotestosterone (IC50 = 52 fiM). Aminoglutethimide was dissolved in acetic acid and used at a final concentration of 0.1% (v/v). 5a-Dihydrotestosterone was dissolved in ethanol and used at a final concentration of 0.4% (v/v). These concentrations of vehicles did not affect the aromatase assay.
To investigate the effect of C8 on aromatase enzyme kinetics, two liver microsome samples per treatment group were chosen at random and incubated with different concentrations of androsten-4-ene 3,17-dione (0-200 /IM) according to the procedure described above. Lineweaver-Burk analysis was performed on the data obtained for each sample by double-reciprocal plots of aromatase activity against substrate concentration.
To determine whether C8 directly affected aromatase activity, different concentrations of C8 were co-incubated for 2 hr at 37°C with liver microsomes prepared from nontreated rats. These concentrations were chosen based on serum concentrations of C8 achieved in rats during a 90-day dietary study 3 and following a single dose of C8 (Hanhijarvi et al., 1982; Ylinen et al, 1989) .
Total cytochrome P450. The concentration of total cytochrome P450 in liver microsomes was calculated from its absorbance spectrum following combination with carbon monoxide (Guengerich, 1982; Omura and Sato, 1964) . The results were expressed as nmol cytochrome P450/mg microsomal protein.
Hepatocyte studies. Hepatocytes were isolated from 260-to 280-g male CD rats by collagenase perfusion (Butterworth et al., 1987) . Briefly, the liver was consecutively perfused in situ with Ca 2+ -and Mg 2+ -free Hanks' balanced salt solution containing 0.5 min ethylene glycol-bis(yS-arrunoethyl ether)-A',A',W,A''-tetraacetic acid and 10 HIM yV-[2-hydroxyethyl] piperazine-JV'-[2-ethanesulfonic acid] (Hepes; pH 7.35), followed by 100 units collagenase (Type IV) per milliliter Williams medium E (WME) containing 2 mM L-glutamine, 50 /ig/ml gentarrucin sulfate, and 10 mM Hepes (WME-G, pH 7.35). The cells were purified through 45% (v/v) Percoll (Kreamer et al., 1986) . Five million cells in 4 ml WME-G supplemented with 1 /IM dexamethasone and ITS + (6.25 //g/ml insulin, 6.25 /xg/ml transferrin, 6.25 ng/ml selenous acid, 1.25 mg/ml BSA, 5.35 //g/ml linoleic acid) were cultured in 25-cm 2 culture flasks which had been precoated with 50% (v/ v) Matrigel at 37°C in a humidified atmosphere of 5% CO 2 :95% air. After a 1-hr preincubation, C8 was added to the culture flasks, and this C8-containing medium was refreshed daily.
The direct effect of different concentrations of C8 on hepatocyte aromatase activity was evaluated after 18, 42, and 66 hr of treatment. These concentrations were selected based on the effective doses on microsomal aromatase activity (Fig. 5 ) and concentrations which were noncytotoxic to rat Leydig cells in vitro (Liu et al., 1996) . The culture medium was replaced with 50 fjM androsten-4-ene-3,17-dione and 2 /iCi/ml [l/?-3 H]androsten-4-ene-3,17-dione in 4 ml C8-free WME-G and returned to the incubator for 3 hr. The samples were processed according to the method described above for microsomal aromatase activity.
Data analysis.
Results are reported as means ± standard error of the mean (SE). Data were analyzed by a one-way analysis of variance (ANOVA). When the corresponding F test for differences among test groups was significant, pairwise comparisons were made with Dunnett's test (p =s 0.05).
To correlate serum estradiol with hepatic aromatase activity, the total aromatase activity for each liver was calculated. The results were expressed as nmol/hr/liver/kg body wt to take into account the effect of C8 on liver and body weights. Standard methods of regression analysis were applied to determine the model which best described the relationship between serum estradiol and hepatic aromatase activity (Draper and Smith, 1981) .
The dose of C8 required to elicit a half-maximum response (EC50) was estimated using ORIGIN (MicroCal Software, Inc., Northampton, MA). Table 1 summarizes the effects of C8 on body, liver, and testes weights. Pair feeding, and doses of at least 20 mg C8/ 3 Unpublished report by The 3M Co. (HWI 6329-100).
RESULTS
kg reduced the mean final body weight compared with the ad libitum control. C8 treatment reduced the daily consumption of diet (data not shown). Since the mean final body weight of rats treated with 40 mg C8/kg was not significantly different from that of its pair-fed control (Table 1) , the C8-induced reduction in body weight most likely results from this decrease in dietary intake. The mean absolute liver weight of the pairfed control rats was significantly lower than that of the ad libitum controls, but not when expressed relative to body weight (Table 1) . Treatment with at least 2 mg C8/kg significantly increased both the absolute and relative liver weights. Compared with the ad libitum control, C8 had no significant effect on the mean absolute weight of the testes, but pair feeding and 20 mg C8/kg significantly increased the mean relative testes weights. The increases in relative weight of the testes were attributed to the decreases in body weight because the value for the 40 mg C8/kg group was not significantly different from that of its pair-fed control (Table 1) .
C8 treatment had no significant effect on testicular aromatase activity (Table 1) , but dose dependently increased hepatic aromatase activity (Vma*) to a maximum of 6-fold above the pair-fed control (Fig. 1 a) . C8 treatment also significantly increased the protein yield of hepatic microsomes at all dose levels ( Table 1) . The total hepatic aromatase activity was calculated for each rat to adjust for the liver and body weight effects of C8. Treatment with C8 produced a dose-related increase in total hepatic aromatase activity, up to 16-fold over the pair-fed control (Fig. lb) . With the exception of the significantly increased protein yield of hepatic microsomes, a dose of 0.2 mg C8/kg had no detectable effect in this study.
Lineweaver-Burk analysis of aromatase data obtained from two hepatic microsome samples per treatment group showed that C8 increased the apparent K m of aromatase for its substrate {ad libitum control, 33 and 46 ^M; pair-fed control, 36 and 33 ^M; 0.2 mg/kg, 43 and 48 ^M; 2 mg/kg, 42 and 99 /XM; 20 mg/kg, 98 and 120 //M; 40 mg/kg, 102 and 122 yM).
The serum concentration of estradiol (Fig. 2) and hepatic aromatase activity were increased by doses of at least 2 mg C8/kg. A significant linear correlation was established between total hepatic aromatase activity and the serum concentration of estradiol ( Fig. 3 ; r 2 = 0.53, p < 0.0001). The individual serum concentrations of estradiol of control rats tended to range widely and were associated with low hepatic aromatase activities. When the data were analyzed from only animals treated with C8, a statistically significant correlation was also established (r 2 = 0.57, p < 0.0001).
Hepatic /3-oxidation activity (Fig. 4a) and total hepatic cytochrome P450 concentration (Fig. 4b) were increased following treatment with C8. These C8-induced increases and changes in other parameters appear to have different sensitivities to each other ( Table 2 ). The estimated EC50 16.7 ± 0.6 17.4 ± 0.5 22.2 ± 0.7* 24.5 ± 0.9* 24.3 ± 0.9* 12.8 ± 0.5* weight Relative (% body weight) 3.8 ± 0.1 4.0 ± 0.1 5.1 ± 0.1* 6.5 ± 0.2* 6.8 ± 0.2* 3.6 ± 0.1 values for C8 on different end points are ranked in decreasing order of potency in Table 2 . The different number of measurements made for each parameter may account for these apparent differences in potency (Table 2) . Thus, when the aromatase data were analyzed from the same six animals chosen for total cytochrome P450 and /3-oxidation assays, a dose-response curve was obtained (not shown) with an estimated EC50 value of 1.61 mg C8/kg which approximates the value generated for induction of /3-oxidation activity. A similar EC50 value of 1.53 mg C8/kg was estimated for serum estradiol when n = 6, compared with that calculated in Table 2 . aromatase activity and serum estradiol, a relationship which indicates that the increased serum concentration of estradiol in C8-treated rats (Cook et ai, 1992 (Cook et ai, , 1994 Biegel et at., 1995) is due to an increased capacity of the liver to synthesize estradiol.
However, there was an apparent discrepancy between the 16-fold maximum increase in total hepatic aromatase activity (Fig. lb) , yet only a 2-fold maximum increase in serum estradiol (Fig. 2) . Co-incubation of liver microsomes with C8 in viXro reduced the apparent aromatase activity (Fig.  5) , but with C8-treated hepatocytes, the initial inhibition of aromatase was followed by an increase in activity (Fig. 6) . The biphasic nature of this response is consistent with cytochrome P450 enzyme induction, a phenomenon characteristic of other cytochrome P450 inhibitors such as the methylenedioxyphenyl compounds (Philpot and Hodgson, 1971/ 1972 ). This induction is probably due to synthesis of new aromatase enzyme because C8 treatment in vivo increased the apparent K m , suggesting a reduced affinity of aromatase for its substrate, and C8 also increased V max for hepatic aromatase activity. Therefore, the apparent discrepancy between the changes in hepatic aromatase activity and serum estradiol is probably due to the ability of C8 to directly inhibit liver aromatase activity. The process of preparing liver microsomes would presumably remove or reduce this inhibitory effect of C8 on aromatase activity in vitro.
The ability of C8 to depress hepatocyte and microsomal aromatase activity in vitro occurs at C8 concentrations simiIncreasing concentrations of C8 reduced the apparent aromatase activity in liver microsomes prepared from control rats (Fig. 5) .
The aromatase activity in control hepatocytes decreased with time in culture. Thus, compared with the 18-hr cultures, the aromatase activity in 42-and 66-hr control cultures declined to 30 and 19%, respectively. The results were expressed as a percentage of the time-matched control to correct for this decrease. Clear dose-related effects of C8 were observed on aromatase activity. Aromatase activity was reduced after 18 and 42 hr of treatment and increased after 66 hr of treatment (Fig. 6) .
DISCUSSION
This study is the first to demonstrate a clear relationship between induction of hepatic aromatase activity and increases in serum estradiol for a peroxisome proliferator. The increased protein yield of hepatic microsomes suggests that C8 induces the endoplasmic reticulum, the site of aromatase (Lephart and Simpson, 1991) and other cytochrome P450 enzymes (Okey, 1990) . Together with the combined effect of C8 to increase both liver weight and hepatic aromatase activity, this provides a large potential for estradiol synthesis. A linear correlation was also established between hepatic lar to those achieved in serum. For example, in male rats, 24 hr after a gavage dose of 2 mg C8, the serum concentration is reported to be 102 /J,M (Hanhijarvi et al., 1982) and 114 /XM following an intraperitoneal dose of 50 mg C8/kg (Ylinen et al., 1989) . Also, rats fed a diet of 0.1, 0.6, 1.9, and 6.5 mg C8/kg/day for 5 weeks had serum C8 concentrations of EC50 represents the dose of C8 which produced a half-maximum response.
* n, number of measurements per group; unless otherwise indicated, n = 15 for all dose levels except 40 mg C8/kg where n = 13.
c Estimated EC50 assuming a maximum response. 15, 129, 240, and 370 fiM, respectively (see footnote 3). We conclude from these data that effective circulating levels of C8 were probably achieved in vivo to suppress estradiol synthesis despite the compensatory induction of liver aromatase activity.
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In addition to C8, three other hepatic peroxisome proliferators, di-(2-ethylhexyl) phthalate, clofibrate Rao et al, 1994) , and Wyeth 14,643 (Cook et al, 1994) , have been shown to increase the serum concentration of estradiol in adult male rats. The increases produced by di-(2-ethylhexyl) phthalate and colfibrate were attributed to reduced metabolism of estradiol by hepatic estrogen hydroxylase . It is not known whether all peroxisome proliferators increase serum estradiol and, if so, whether this occurs through a decrease in hepatic estradiol metabolism, induction of aromatase activity, or both. It is unlikely, however, that the increase in serum estradiol produced by C8 is caused by an increased availability of substrate for aromatase. First, the circulating level of testosterone is present in nanomolar concentrations, far in excess of the picomolar levels of estradiol (Cook et al, 1992) . Second, C8 treatment has been shown to depress rather than increase the baseline and human chorionic gonadotropin (hCG)-stimulated concentrations of testosterone in rats (Cook et al, 1992) and in cultured rat Leydig cells (Biegel et al, 1995) . This decrease in testosterone release from cultured Leydig cells was associated with a biphasic effect on estradiol production, to initially inhibit and later increase the release of estradiol, suggesting induction of Leydig cell aromatase (Biegel etal, 1995) . However, as in a previous study (Biegel et al, 1995) , we found that C8 treatment did not affect testicular aromatase activity. The disagreement between the in vivo and in vitro observations may be attributable to the endocrine and paracrine regulatory mechanisms (Skinner, 1991) which would correct alterations in Leydig cell function in vivo, but which are absent in vitro. For example, we reported recently that the hCG-stimulated release of testosterone from Leydig cells isolated from C8-treated rats was greater than that from cells of control animals (Biegel et al, 1995) . To restore homeostasis, endocrine and paracrine feedback mechanisms probably attempt to normalize the inhibitory effect of C8 on Leydig cell function. This would suggest that the Leydig cells in vivo undergo some compensatory up-regulation of function/induction of enzyme(s) in response to C8. Thus, for Leydig cell aromatase activity, the homeostatic mechanisms may serve to maintain normal levels in vivo. The long-term consequences of such compensatory mechanisms are unknown.
Another explanation is that the relatively low levels of aromatase in the testes (Biegel et al, 1995) could indicate that other sources of estradiol are more important. It was noted that low hepatic aromatase activities in control rats were associated with a wide range of serum estradiol concentrations (Fig. 3) . This finding could suggest that the serum concentration of estradiol is not dependent on hepatic aromatase activity in untreated rats. Consequently, under normal circumstances, the nonhepatic sources of estradiol may derive mainly from other tissues such as the testes, skeletal muscle, and adipose tissue which also contain aromatase activity (Biegel et al, 1995) . However, when induced by C8, the hepatic aromatase activity appears to become a major source and determinant of the serum level of estradiol. The relative proportion of circulating estradiol which derives from the rat liver is not known, but the testicular contribution has been calculated to be 21 % (Dorrington and Khan, 1993 ). An alternative explanation for the lack of effect of C8 on testicular aromatase in vivo is that measurements on microsomes prepared from whole testes may mask specific changes in aromatase activity in Leydig cells.
The results reported herein suggest that the increase in serum estradiol produced by C8 is caused, at least in part, by direct induction of hepatic aromatase activity. This elevation in serum estradiol has been suggested to represent an important component in Leydig cell tumorigenesis in rats (Cook et al, 1992) . However, many studies show that estrogens do not stimulate Leydig cells. For example, estradiol treatment reduces the function of rat Leydig cells both in vitro (Van Beurden et al, 1976) and in vivo (Chen et al, 1977; Hsueh et al, 1978) , and estrogenic compounds do not induce Leydig cell tumors, but rather produce testicular atrophy (Gibson et al, 1967; Marselos and Tomatis, 1993; Schardein, 1980; Schardein et al, 1970) . The hCG-stimulated synthesis of DNA in Leydig cells has been shown to be inhibited by estradiol in vitro (Abney and Carswell, 1986) and in vivo (Saez etal, 1978) . Furthermore, combined injections of estradiol and hCG are reported to prevent the regeneration of Leydig cells in rats which had been depleted of them with the specific cytotoxin ethane dimethyl sulfonate (Abney and Myers, 1991) . Together with the pubertal decline in estradiol which accompanies the proliferation of Leydig cells, these observations appear to argue against our suggestion that a sustained increase in serum estradiol produces Leydig cell hyperplasia and tumors. However, an estrogeninduced inhibition of Leydig cell function, as determined by steroidogenic capacity, cannot be tied to inhibition of cell proliferation, since these effects probably occur through separate intracellular signaling and effector pathways. Further, nonphysiologically relevant micromolar concentrations of estrogen have been used in the past, which suppress serum LH levels and produce severe testicular atrophy. Previous studies have shown that both the Wyeth 14,643-and C8-induced increases in serum estradiol do not suppress LH or produce testicular atrophy (Cook et al, 1992 (Cook et al, , 1994 . We believe that long-term exposure to more physiologically appropriate concentrations of estradiol may be involved in the proliferation of Leydig cells.
In this context, Fischer-344 rats have a spontaneous incidence of almost 100% Leydig cell tumors by 2 years of age which appears to correspond with its age-dependent increase in serum estradiol (Turek and Desjardins, 1979) . This apparent relationship is absent in the CD rat which has a low incidence of Leydig cell tumors (Lang, 1992) and an agerelated decrease in serum estradiol (Cook et al, 1994) . Furthermore, the potencies of C8 and Wyeth 14,643 to produce Leydig cell tumors in rats correlate with their abilities to maintain increased serum estradiol levels over 2 years (Cook et al, 1994) . The relationship between a sustained increase of physiologically relevant concentrations of estradiol and the production of Leydig cell hyperplasia and tumors can only be resolved in a 2-year rat bioassay. This relationship is currently under investigation.
